Search the Newsreel

AMRX Q2 Deep Dive: Diversified Product Mix and Biosimilars Strategy Shape Guidance

AMRX Q2 Deep Dive: Diversified Product Mix and Biosimilars Strategy Shape Guidance Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 9.9% year on year to $796.2 million. The company's full-year revenue guidance of $3.15 …

Amneal Pharmaceuticals (AMRX) Stock Asks If Profit Momentum Can Endure

Amneal Pharmaceuticals (AMRX) reported a strong Q2 with increased revenue and adjusted EPS, leading to a raised full-year outlook. While the company is transitioning towards higher-margin biosimilars and injectables, investor concern centers on the sustainability of this profit momentum given increased capital expenditure and …

Amneal Pharmaceuticals Inc (AMRX) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ...

AMRX Down Despite Q2 Earnings Beat, 2026 Revenue Outlook Raised

Amneal Pharmaceuticals AMRX reported second-quarter 2026 adjusted earnings of 30 cents per share, which beat the Zacks Consensus Estimate of 24 cents. Earnings increased 20% year over year, driven by strong performance across the company's three business segments. Total revenues of $796 million in …

AMN Healthcare Services Inc (AMN) Valuation: PE, PB & Fair Value Analysis

AMN Healthcare Services Inc (AMN) has a current valuation score of 9.09, placing it 9th out of 75 in the Healthcare Providers & Services industry. The company's P/E ratio is -39.20, which is significantly below its recent high and slightly above its recent low. …

Amneal projects 2026 revenue of $3.1B-$3.2B while raising capex to about $150M

Earnings Call Insights: Amneal Pharmaceuticals (AMRX) Q2 2026 MANAGEMENT VIEW * "Amneal is in the midst of the most transformative period in our company's history," said (Co-Founder, Co-CEO, President & Director Chirag Patel), adding the company is "growing as one of the America's leading …

Earnings call transcript: Amneal tops Q2 2026 estimates, but shares slip

Amneal Pharmaceuticals reported stronger-than-expected Q2 2026 earnings and revenue, with adjusted EPS at $0.30 and revenue at $796.2 million, beating analyst estimates. Despite the strong performance and raised full-year guidance, the stock saw a slight premarket dip, potentially due to its proximity to its …

Compared to Estimates, Amneal (AMRX) Q2 Earnings: A Look at Key Metrics

For the quarter ended June 2026, Amneal Pharmaceuticals (AMRX) reported revenue of $796.2 million, up 9.9% over the same period last year. EPS came in at $0.30, compared to $0.25 in the year-ago quarter. The reported revenue represents a surprise of +3.7% over the …

Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Surpass Estimates

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.3 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.25 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Amneal (NASDAQ:AMRX) Beats Expectations in Strong Q2 CY2026, Stock Jumps 15.9%

Amneal (NASDAQ:AMRX) Beats Expectations in Strong Q2 CY2026, Stock Jumps 15.9% Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q2 CY2026 results topping the market's revenue expectations , with sales up 9.9% year on year to $796.2 million. The company's full-year revenue guidance of $3.15 billion …

Amneal: Q2 Earnings Snapshot

Amneal Pharmaceuticals (AMRX) Wins FDA Nod For Iohexol, Is The Upside Already Priced In?

Amneal Pharmaceuticals (AMRX) recently received FDA approval for additional strengths and vial sizes of its iohexol injection, boosting its product portfolio and contributing to strong share price momentum. While analysts consider the stock about 5% overvalued with a fair value of $18.25, Simply Wall …

Amneal Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:AMRX) 2026-07-30

Image source: The Motley Fool. DATE Thursday, July 30, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Head of Investor Relations - Anthony DiMeoCo-Founder and Co-Chief Executive Officer - Chirag PatelCo-Founder and Co-Chief Executive Officer - Chintu PatelChief Financial Officer - Anastasios KonidarisSpecialty - Joe …

Amneal Debt Repricing Expected to Save About $12M a Year

AMN Healthcare Services (AMN) to Announce Earnings on Thursday

Amneal Reports Second Quarter 2026 Financial Results

Amneal Pharmaceuticals reported strong second quarter 2026 financial results with net revenue up 10% to $796 million and adjusted EBITDA increasing 12% to $206 million. The company raised its full-year 2026 guidance, citing broad-based performance and confidence in its diversified portfolio, including anticipated contributions …

Amneal (AMRX) Reports Q2: Everything You Need To Know Ahead Of Earnings

Amneal (AMRX) Reports Q2: Everything You Need To Know Ahead Of Earnings Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) will be announcing earnings results this Thursday before market hours. Here's what to expect. Amneal beat analysts' revenue expectations last quarter, reporting revenues of $722.5 million, up …

AMN Healthcare Services Inc (AMN) Institutional Confidence

AMN Healthcare Services Inc (AMN) has an institutional shareholding score of 10.00, placing it first in the Healthcare Providers & Services industry. The institutional shareholding proportion is 107.06%, a decrease of 22.20% quarter-over-quarter. James Simons is the largest institutional shareholder, with other significant holders …

AMN Healthcare Services Inc (AMN) Financial Health: Profitability & Balance Sheet Analysis

AMN Healthcare Services Inc (AMN) boasts a robust financial score of 9.25, ranking 6th in its industry. The company reported a significant year-over-year revenue increase of 99.90% to $1.38 billion, alongside a net profit surge of 5792.86%. While key financial metrics such as cash …

Spotting Winners: Amneal (NASDAQ:AMRX) And Generic Pharmaceuticals Stocks In Q1

Amneal Pharmaceuticals stock hits 52-week high at 18.59 USD

Amneal Pharmaceuticals stock (AMRX) recently hit a 52-week high of $18.59, reflecting a 123.61% increase over the past year. Despite its strong performance, InvestingPro analysis suggests the stock is currently overvalued. The company also reported strong Q1 2026 results and received FDA approvals for …

Truist Financial Maintains AMN Healthcare Services(AMN.US) With Buy Rating, Maintains Target Price $40

Truist Financial has reiterated its Buy rating for AMN Healthcare Services (AMN.US) and maintained its price target of $40. This indicates a continued positive outlook from the firm regarding the company's stock performance.

(AMN) Risk Channels and Responsive Allocation

This article provides a detailed AI-driven stock analysis for Amn Healthcare Services Inc (NYSE: AMN), highlighting weak near-term sentiment despite long-term strength. It outlines specific trading strategies categorized by risk profile and holding period, including position, momentum breakout, and risk hedging strategies. The analysis …

Are Business Services Stocks Lagging AMN Healthcare Services (AMN) This Year?

For those looking to find strong Business Services stocks, it is prudent to search for companies in the group that are outperforming their peers. AMN Healthcare Services (AMN) is a stock that can certainly grab the attention of many investors, but do its recent …

Amneal Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:AMRX

AMN Healthcare Services Inc (AMN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of AMN Healthcare Services Inc (AMN), detailing its price momentum score of 3.58 and its trading range between a resistance of $36.20 and support of $30.78. It presents a breakdown of various technical indicators, such as MACD, RSI, …

AMN Healthcare Services Inc (AMN) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for AMN Healthcare Services Inc (AMN), detailing its volatility, financial, and investment risks. The company currently holds a risk assessment score of 5.69, positioning it at 35 out of 75 in the Healthcare Providers & Services industry. Key …

Amneal Pharmaceuticals, Inc. Class A Revenue Breakdown – FWB:2DT

Amneal Pharmaceuticals, Inc. Class A (FWB:2DT) generated 2.57 billion EUR last year, with its Affordable Medicines segment being the top performer contributing 1.49 billion EUR. The primary revenue sources by region were the United States, India, and Ireland. The company's total revenue saw a …

AMN Healthcare Services Inc (AMN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

The article provides a detailed revenue breakdown for AMN Healthcare Services Inc (AMN) across its various business segments and geographical regions. It highlights that in FY2025, Temporary Staffing accounted for the vast majority of revenue at 84.13% ($2.30 billion), with Technology-enabled services, Permanent Placement, …

How Investors May Respond To Amneal Pharmaceuticals (AMRX) Expanding Its Iohexol Generic Portfolio Across OMNIPAQUE Formats

Amneal Pharmaceuticals has received FDA approval for additional strengths and vial sizes of its iohexol injection, making it the first generic supplier for various OMNIPAQUE-referenced presentations. This expansion reinforces Amneal's injectable and hospital portfolio, potentially supporting its revenue and earnings forecasts, but also highlights …

AMN Healthcare Services Inc (AMN) Cash Flow

This article provides a detailed cash flow statement for AMN Healthcare Services Inc (AMN), presenting quarterly and annual data for operating, investing, and financing activities. It includes year-over-year percentage changes for various cash flow components and explains the significance of operating, investing, and financing …

AMN Healthcare Services Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance | TradingKey

This article provides a detailed company profile for AMN Healthcare Services Inc (AMN), a provider of healthcare talent solutions in the U.S. It covers the company's business segments, key financial figures like market cap and revenue, and lists important executive and board members. The …

AMN Healthcare Services, Inc. Revenue Breakdown – DUS:HCQ

This article provides a revenue breakdown for AMN Healthcare Services, Inc. (DUS:HCQ), detailing its top-performing segment, Nurse and Allied Solutions, which generated 1.40 billion EUR last year. The company's total revenue was 2.32 billion EUR, with the largest contribution coming from the United States.

AMN Income Statement

This article provides a detailed quarterly and annual income statement for AMN Healthcare Services Inc (AMN). It includes vital financial metrics like total revenue, cost of revenue, operating expenses, operating profit, income before tax, net income, and basic and diluted earnings per share (EPS) …

Amneal Pharmaceuticals (AMRX) Stock May Be Fully Priced Following Its 4.7x Run

Amneal Pharmaceuticals (AMRX) has experienced a significant 4.7x share price increase over the last three years, leading to a valuation that appears expensive compared to industry averages. Despite recent FDA approval for its iohexol injection portfolio, the stock's current P/E ratio of 46.8x is …

AMN|AMN Healthcare Services Inc|Price:32.890|Chg%:-0.170

This article provides an analysis of AMN Healthcare Services Inc. (AMN) based on TradingKey's stock scoring system. It highlights that AMN's fundamentals are healthy with high growth potential, its valuation is considered fairly valued, and institutional ownership is very high. The article also notes …